Clinical trials: Anticoagulant
Anticoagulants
Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence
Inconsistent anticoagulation therapy in AF patients is associated with a higher risk of stroke and abnormal bleeding. The purpose of the study is to investigate the efficacy of a health belief model based self-management of oral…
- Trial name
- NCT03864900
- Testing
- The medication adherence intervention
- Where
- 2 sites in Taiwan
- Volunteers
- 72 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Anticoagulants; Circulating, Hemorrhagic Disorder, Femoral Neck Fractures
Evaluation of Perioperative Management of Curative Anticoagulants in the Geriatric Perioperative Unit in Patient Hospitalized for Femoral Neck Fracture.
Pilot study to evaluate the management of curative anticoagulant prescriptions pre- and postoperatively in elderly patients hospitalized for femoral neck fracture.
- Trial name
- ANTICOGER (NCT05286671)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Thrombocytopenia, Thrombosis
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT)…
- Trial name
- NCT00039858
- Testing
- Argatroban
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Encysive Pharmaceuticals
Anticoagulants, Compliance, Medication
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
The novel oral anticoagulants such as rivaroxaban, apixaban and dabigatran, specifically target either thrombin or factor Xa/IIa.
- Trial name
- NCT03666962
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Cui Yimin
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral)
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
Endothermal heat-induced thrombosis (EHIT) is a thrombotic complication specific to endovenous thermal ablation of the great saphenous vein (GSV), for which no prophylactic regimen is standardized.
- Conditions
- Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
- Trial name
- NCT07699796
- Testing
- Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 564 people
- Sponsor
- Heart, Artery, and Vein Center of Fresno
Thromboembolic Event
Elaboration of a Prioritization Score for Pharmaceutical Interviews in Patients Treated With Oral Anticoagulants
Oral anticoagulants have a prominent place in the strategy of prevention and treatment of thromboembolic diseases, especially in patients with atrial fibrillation.
- Trial name
- NCT06100380
- Testing
- Survey
- Where
- France
- Volunteers
- 197 people
- Sponsor
- CHU de Reims
Contrast Agents and Oral Factor Xa Inhibitor
The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
The aim of this study is to evaluate the effect of iohexol as a contrast agent on the anticoagulant activity of oral factor Xa inhibitors.
- Trial name
- NCT04611386
- Testing
- computerized tomography
- Where
- Turkey (Türkiye)
- Volunteers
- 65 people
- Sponsor
- Bursa Postgraduate Hospital
Atrial Fibrillation
Validation of Predictors of OAC Initiation Using EMR Data
The objectives of this study are, first, to identify select clinical covariates from electronic medical records (EMR) that might be associated with initiation of oral anticoagulant medications (dabigatran or warfarin) in patients…
- Trial name
- NCT03006341
- Testing
- Dabigatran etexilate, Warfarin
- Where
- United States
- Volunteers
- 140,187 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin.
- Trial name
- DOAC LVAD (NCT04865978)
- Testing
- Apixaban, Warfarin, LVAD implant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palak Shah
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Venous Thromboembolism, Deep Venous Thrombosis
Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their operative procedures. Thus, plastic \& reconstructive surgery patients are among those at highest risk for anticoagulant-associated…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
- Trial name
- NCT03212365
- Testing
- Fixed dose, Variable dose
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- University of Utah
Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Anticoagulants
VTE and the Related Factors Associated With Higher Rates of PE After a DVT in Southwestern China
Little is known about the current management status of venous thromboembolism (VTE) in Southwestern China. We aimed to investigate the status of anticoagulant administration in VTE in Southwestern China and assess the potential…
- Trial name
- NCT05464901
- Volunteers
- 500 people
- Sponsor
- Wei Huang
Arthroplasty, Replacement, Knee
A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery
To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery
- Trial name
- PEARL (NCT00595426)
- Testing
- YM150, Warfarin
- Where
- 54 sites in United States, Canada
- Volunteers
- 685 people
- Sponsor
- Astellas Pharma Inc
Myocardial Infarction, Acute, Left Ventricular Thrombus
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
APERITIF is a prospective randomized open-label, blinded end-point (PROBE) trial, nested in the ongoing the "FRENCHIE" registry, a French multicenter prospective observational study granted by "ANR-RHU Grand Emprunt", in which…
- Trial name
- APERITIF (NCT05077683)
- Testing
- Rivaroxaban 2.5 MG [Xarelto], DAPT strategy
- Where
- France
- Volunteers
- 560 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation
Health-related Quality of Life in Patients on Anticoagulants
The present study has been designed to describe the health-related quality of life in patients with non valvular atrial fibrillation who have been prescribed a specific anticoagulant treatment for their non valvular atrial…
- Trial name
- RE-QUOL (NCT03134911)
- Testing
- DOAC or VKA, VKA
- Where
- 39 sites in Spain
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart.
- Trial name
- EMANATE (NCT02100228)
- Testing
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Where
- 165 sites in United States, Belgium and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Pfizer
Valve Heart Disease, Anticoagulants; Increased
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months oral anticoagulation therapy after operation.
- Trial name
- REDUCE (NCT03885180)
- Testing
- Warfarin Sodium
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Patient Undergoing Diagnostic Coronary Angiography
Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Subgroup of Patients on Oral Anticoagulants
To investigate whether omitting systemic anticoagulation during transradial coronary angiography and/or a distal radial access reduce the risk of postprocedural radial artery occlusion
- Trial name
- RAPID-2 (NCT04362020)
- Testing
- Distal radial access
- Volunteers
- 400 people
- Sponsor
- University of Luebeck
Atrial Fibrillation
Anticoagulant Utilization Pattern
This study plans to describe utilization patterns for oral anticoagulants over time in patients with non-valvular atrial fibrillation at risk for stroke using electronic claims data from a United States commercial insurance…
- Trial name
- NCT01847560
- Where
- United States
- Volunteers
- 333,664 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Failure, Vascular Graft Occlusion
A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis
The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid…
- Trial name
- NCT00074620
- Testing
- PEG-hirudin
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Speedel Pharma Ltd.